## WHAT IS CLAIMED IS:

1. A compound having a structural Formula I,



I

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

A is:  or  ;

E is: O, S or $NR^{14}$;

W is:  , hydrogen, $C_1$-$C_6$ alkyl, $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, haloalkyl or acyl;

Q is: $-C(O)OR^6$ or $R^{6A}$;

X is: a bond, C, O, S or $S[O]_p$;

Y is: a bond, S, C or O;

Z is:
a) aliphatic group,
b) aryl,
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from $R^{15}$;

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

v is: 1 or 2;

$R^1$ is: hydrogen, wherein when Z is phenyl or naphthyl and $R^2$ is H , $R^1$ is not H,

haloalkyl,

$C_1$-$C_6$ alkyl,

$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy,

$C_1$-$C_6$ alkyl-aryl,

$C_2$-$C_6$ alkenyl,

$C_2$-$C_6$ alkynyl,

$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,

$C_1$-$C_6$ alkoxy,

aryl, or

$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{1a}$ and $R^{1b}$ are each independently:

hydrogen,

$C_1$-$C_6$ alkyl, or

$R^1$ and $R^{1a}$, $R^1$ and $R^{1b}$, $R^2$ and $R^{1a}$, $R^2$ and $R^{1b}$ or $R^{1a}$ and $R^{1b}$ together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of $R^{1a}$ and $R^{1b}$ is not hydrogen;

$R^2$ is: hydrogen,
haloalkyl,
$C_1$-$C_6$ alkyl,
$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy,
$C_1$-$C_6$ alkyl-aryl,
$C_2$-$C_6$ alkenyl,
$C_2$-$C_6$ alkynyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
$C_1$-$C_6$ alkoxy,
aryl, or
$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl. cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{2a}$ is: hydrogen, halo or $C_1$-$C_6$ alkyl and wherein $R^2$ and $R^{2a}$ together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^3$ is: hydrogen,
halo,
cyano,
haloalkyl,
$C_1$–$C_6$ alkyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
($C_1$–$C_4$ alkyl)-heterocyclyl. wherein the heterocyclyl being optionally substituted with oxo,
($C_1$–$C_4$ alkyl)-$NR^7C(O)_nR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^4$ and $R^5$ are each independently:

hydrogen,

halo,

$C_1$-$C_6$ alkyl

$C_1$-$C_6$ alkoxy;

aryloxy;

$N(R^8)_2$,

$SR^8$ or

$R^4$ and $R^5$ together being a 3- to 8-membered ring;

$R^6$ is: hydrogen, $C_1$-$C_6$ alkyl or aminoalkyl;

$R^{6A}$ is: carboxamide, $C_1$-$C_3$ alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

$R^7$ is: hydrogen or $C_1$-$C_6$ alkyl;

$R^8$ and $R^9$ are each independently:

hydrogen, $C_1$-$C_6$ alkyl, aryl, heteroaryl, or heterocyclyl, and

wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl and $C_1$-$C_6$ alkoxy;

$R^{14}$ is: hydrogen, aryl, $C_1$-$C_6$ alkyl, or $C_1$-$C_6$ alkyl-$COOR^6$, and

wherein aryl and alkyl being optionally substituted with one or more groups independently selected from $R^{15}$; and

$R^{15}$ is: hydrogen, nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$. $SR^8$, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

2. The compound Claim 1, wherein X and Y are respectively S and O; S and C; or C and O.

3. The compound of Claim 2, wherein Z is $C_1$-$C_6$ alkyl, aryl or heteroaryl.

4. The compound of Claim 3. wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl; 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

5. The compound of Claim 4. wherein $R^1$ is $C_3$-$C_6$ alkyl or $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl; $R^2$ and $R^3$ are each independently $C_1$-$C_3$ alkyl; and r is 1.

6. The compound Claim 5. wherein X is positioned para to Y; and $R^3$ is positioned ortho to Y.

7. A compound having a structural Formula II,



II

and pharmaceutically acceptable salts, solvates. hydrates or stereoisomers thereof, wherein:

Q is: $-C(O)OR^6$ or $R^{6A}$;

X is: a bond, C, O, S or $S[O]_p$;

Y is: a bond, S, C or O;

Z is: a) aliphatic group,
b) aryl,
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
f) heterocyclyl;
wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from $R^{15}$;

m and n' are each independently: 0, 1, 2, 3 or 4;
n is: 0, 1, 2 or 3;
p is: 1 or 2;
r is: 1, 2, 3 or 4;

$R^1$ is: aryl,
haloalkyl,
$C_1$-$C_6$ alkyl,
$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy,
$C_1$-$C_6$ alkyl-aryl,
$C_2$-$C_6$ alkenyl,
$C_2$-$C_6$ alkynyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
$C_1$-$C_6$ alkoxy or
$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{1a}$ and $R^{1b}$ are each independently:

hydrogen,

$C_1$-$C_6$ alkyl, or

$R^1$ and $R^{1a}$, $R^1$ and $R^{1b}$, $R^2$ and $R^{1a}$, $R^2$ and $R^{1b}$ or $R^{1a}$ and $R^{1b}$ together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of $R^{1a}$ and $R^{1b}$ is not hydrogen;

$R^2$ is: hydrogen,

haloalkyl,

$C_1$-$C_6$ alkyl,

$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy,

$C_1$-$C_6$ alkyl-aryl,

$C_2$-$C_6$ alkenyl,

$C_2$-$C_6$ alkynyl,

$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,

$C_1$-$C_6$ alkoxy,

aryl, or

$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{2a}$ is: hydrogen, halo or $C_1$-$C_6$ alkyl and wherein $R^2$ and $R^{2a}$ together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^3$ is: hydrogen,

halo,

cyano,

haloalkyl,

$C_1$–$C_6$ alkyl,

$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,

($C_1$–$C_4$ alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,

($C_1$–$C_4$ alkyl)-$NR^7C(O)_nR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^4$ and $R^5$ are each independently:

hydrogen,

halo,

$C_1$-$C_6$ alkyl

$C_1$-$C_6$ alkoxy;

aryloxy;

$N(R^8)_2$,

$SR^8$ or

$R^4$ and $R^5$ together being a 3- to 8-membered ring;

$R^6$ is: hydrogen, $C_1$-$C_6$ alkyl or aminoalkyl;

$R^{6A}$ is: carboxamide, $C_1$-$C_3$ alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

$R^7$ is: hydrogen or $C_1$-$C_6$ alkyl;

$R^8$ and $R^9$ are each independently:

hydrogen, $C_1$-$C_6$ alkyl, aryl, heteroaryl, or heterocyclyl, and

wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl and $C_1$-$C_6$ alkoxy;

$R^{15}$ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, $SR^8$, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

8. The compound Claim 7, wherein X and Y are respectively S and O; S and C; or C and O.

9. The compound of Claim 8, wherein Z is $C_1$-$C_6$ alkyl, aryl or heteroaryl.

10. The compound of Claim 9, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

11. The compound of Claim 10, wherein $R^1$ is $C_3$-$C_6$ alkyl or $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl; $R^2$ and $R^3$ are each independently $C_1$-$C_3$ alkyl; and r is 1.

12. The compound Claim 11, wherein X is positioned para to Y; and $R^3$ is positioned ortho to Y.

13. The compound of Claim 7, wherein the compound having a structural Formula III.



III

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n is: 1 or 2;

r is: 1, 2, 3, or 4;

X is: S or C;

Y is: C or O;

Z is: aryl or a 5- to 10-membered heteroaryl,

wherein aryl and heteroaryl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^1$ and $R^2$ are each independently: $C_1$-$C_6$ alkyl or $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl; and

$R^{1a}$ and $R^{1b}$, $R^3$, $R^4$ and $R^5$ are each independently: hydrogen or $C_1$-$C_6$ alkyl.

14. The compound of Claim 13, wherein the compound having a structural Formula IV,



IV

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1, 2, 3, 4, or 5;

$R^8$ and $R^9$ are each independently:

hydrogen, $C_1$-$C_6$ alkyl, aryl, heteroaryl, or heterocyclyl,

wherein alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl and $C_1$-$C_6$ alkoxy: and:

$R^{12}$ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryl, heteroaryl, aryloxy, oxo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, $SR^8$, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

15. The compound of Claim 14, wherein the compound having a structural Formula V,



V

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein $R^1$ and $R^2$ are each independently $C_1$-$C_4$ alky or $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl; $R^3$ is $C_1$-$C_4$ alky; $(R^{12})_1$ is halo, haloalkyl, or haloalkyloxy; and $(R^{12})_2$ is F, Cl or Br.

16. The compound of Claim 15, wherein $R^1$ is methyl, ethyl, propyl, clcylopropyl, cycloproylmethyl, cyclobutyl: $R^3$ is methyl and $(R^{12})_1$ is $OCF_3$.

17. A compound having a structural Formula VI,



VI

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

X is: a bond, C, O, S or $S[O]_p$;

Y is: a bond, S, C or O;

Z is: heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S, and wherein heteroaryl being optionally substituted with one or more groups selected from $R^{15}$;

n is: 0, 1, 2 or 3;

n' is: 0, 1, 2, 3 or 4;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

$R^1$ is: hydrogen,
haloalkyl,
$C_1$-$C_6$ alkyl,
$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy,
$C_1$-$C_6$ alkyl-aryl,
$C_2$-$C_6$ alkenyl,
$C_2$-$C_6$ alkynyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
$C_1$-$C_6$ alkoxy,
aryl, or
$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{1a}$ and $R^{1b}$ are each independently:
hydrogen,
$C_1$-$C_6$ alkyl, or
$R^1$ and $R^{1a}$, $R^1$ and $R^{1b}$, $R^2$ and $R^{1a}$, $R^2$ and $R^{1b}$ or $R^{1a}$ and $R^{1b}$ together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of $R^{1a}$ and $R^{1b}$ is not hydrogen;

$R^2$ is: hydrogen,
haloalkyl,
$C_1$-$C_6$ alkyl,
$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy.
$C_1$-$C_6$ alkyl-aryl,
$C_2$-$C_6$ alkenyl,
$C_2$-$C_6$ alkynyl,

$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
$C_1$-$C_6$ alkoxy,
aryl, or
$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{2a}$ is: hydrogen, halo or $C_1$-$C_6$ alkyl and wherein $R^2$ and $R^{2a}$ together being a 3- to 8-membered ring: and wherein alkyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^3$ is: hydrogen,
halo,
cyano,
haloalkyl,
$C_1$–$C_6$ alkyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
($C_1$–$C_4$ alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,
($C_1$–$C_4$ alkyl)-$NR^7C(O)_pR^9$, and
wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^6$ is: hydrogen, $C_1$-$C_6$ alkyl or aminoalkyl;

$R^7$ is: hydrogen or $C_1$-$C_6$ alkyl;

$R^8$ and $R^9$ are each independently:
hydrogen, $C_1$-$C_6$ alkyl, aryl, heteroaryl, or heterocyclyl, and
wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano,

hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl and $C_1$-$C_6$ alkoxy; and

$R^{15}$ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, $SR^8$, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

18. The compound of Claim17, wherein the compound having a structural Formula VII,



VII

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1, 2, 3, or 4;

T is: O, $NR^{1c}$ or S;

$R^{1c}$ is: hydrogen or $C_1$-$C_6$ alkyl;

$R^{10}$ and $R^{11}$ are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, $C_1$-$C_6$ alkyl or $C_1$-$C_6$ alkoxy; and

wherein alkyl, aryloxy, and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$.

19. The compound of Claim 18, wherein the compound having a structural Formula VIII,



VIII

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1 or 2;

$R^1$ is: $C_3$-$C_5$ alky or $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl;

$R^2$ and $R^3$ are each independently: $C_1$-$C_3$ alkyl;

$R^{10}$ is: halo, haloalkyl or $C_1$-$C_3$ alkyl, and

wherein $R^{10}$ being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring: and

$R^{11}$ is: hydrogen or $C_1$-$C_6$ alkyl.

20. The compound of Claim 19, wherein $R^{10}$ is Cl, F, Br, $CH_3$ or $CF_3$ being substituted at a position 5 of benzothiophenyl ring.

21. A compound having a structural Formula IX,



IX

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is: O, S or $NR^{14}$;

W is:  , hydrogen, $C_1$-$C_6$ alkyl, $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, haloalkyl or acyl:

Q is: $-C(O)OR^6$ or $R^{6A}$:

X is: a bond, C, O, S or $S[O]_p$:

Y is: a bond, S, C or O:

Z is:
a) aliphatic group,
b) aryl,
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from $R^{15}$:

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

v is: 1 or 2;

$R^1$ is: hydrogen,
haloalkyl,
$C_1$-$C_6$ alkyl,
$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy.

$C_1$-$C_6$ alkyl-aryl,
$C_2$-$C_6$ alkenyl,
$C_2$-$C_6$ alkynyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
$C_1$-$C_6$ alkoxy,
aryl, or
$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{1a}$ and $R^{1b}$ are each independently:
hydrogen,
$C_1$-$C_6$ alkyl, or
$R^1$ and $R^{1a}$, $R^1$ and $R^{1b}$, $R^2$ and $R^{1a}$, $R^2$ and $R^{1b}$ or $R^{1a}$ and $R^{1b}$ together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of $R^{1a}$ and $R^{1b}$ is not hydrogen;

$R^2$ is: hydrogen.
haloalkyl.
$C_1$-$C_6$ alkyl.
$C_1$-$C_6$ alkyl-$C_1$-$C_6$ alkoxy,
$C_1$-$C_6$ alkyl-aryl.
$C_2$-$C_6$ alkenyl,
$C_2$-$C_6$ alkynyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
$C_1$-$C_6$ alkoxy.
aryl, or
$R^1$ and $R^2$ together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^{2a}$ is: hydrogen, halo or $C_1$-$C_6$ alkyl and wherein $R^2$ and $R^{2a}$ together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^3$ is: hydrogen,
halo,
cyano,
haloalkyl,
$C_1$–$C_6$ alkyl,
$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl,
($C_1$–$C_4$ alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,
($C_1$–$C_4$ alkyl)-$NR^7C(O)_pR^9$, and
wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from $R^{15}$;

$R^4$ and $R^5$ are each independently:
hydrogen,
halo,
$C_1$-$C_6$ alkyl
$C_1$-$C_6$ alkoxy;
aryloxy:
$N(R^8)_2$,
$SR^8$ or
$R^4$ and $R^5$ together being a 3- to 8-membered ring;

$R^6$ is: hydrogen, $C_1$-$C_6$ alkyl or aminoalkyl:

$R^{6A}$ is: carboxamide. $C_1$-$C_3$ .alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

$R^7$ is: hydrogen or $C_1$-$C_6$ alkyl;

$^{8}$ and $R^{9}$ are each independently:

hydrogen, $C_1$-$C_6$ alkyl, aryl, heteroaryl. or heterocyclyl, and

wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo. $C_1$-$C_6$ alkyl and $C_1$-$C_6$ alkoxy;

$R^{14}$ is: hydrogen, aryl, $C_1$-$C_6$ alkyl, or $C_1$-$C_6$ alkyl-$COOR^{6}$, and

wherein aryl and alkyl being optionally substituted with one or more groups independently selected from $R^{15}$; and

$R^{15}$ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, $N(R^{8})_2$, $NR^{8}S(O)_2R^{9}$, $NR^{8}C(O)_pR^{9}$, $C(O)NR^{8}R^{9}$, $C(O)_pR^{8}$, $SR^{8}$, $S(O)_pR^{8}$ or $S(O)_2NR^{8}R^{9}$.

22. The compound of Claim 21. wherein the compound having a structural Formula X:



X

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n and q are each independently: 1, 2. 3 or 4;

T is: O. $NR^{1c}$ or S;

X is: C, O or S;

$R^{1}$ is: hydrogen, $C_1$-$C_6$ alkyl or $(CH_2)_n$-$C_3$-$C_6$ cycloalkyl;

$R^{1a}$. $R^{1b}$. $R^{1c}$ and $R^{2}$ are each independently: hydrogen or $C_1$-$C_6$ alkyl: and

$R^{10}$ and $R^{11}$ are each independently:

hydrogen. nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy. aryloxy,

$C_1$-$C_6$ alkyl or $C_1$-$C_6$ alkoxy; and wherein alkyl, alkoxy and aryloxy being optionally substituted with one or more groups selected from $R^{15}$.

23. The compound of Claim 22. wherein the compound having a structural Formula XI:



XI

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1 or 2;

E is O, S or $NR^{14}$;

$R^1$, $R^2$ and $R^{11}$ are each independently: $C_1$-$C_4$ alkyl;

$R^{10}$ is: Cl, F, Br, $CH_3$ or $CF_3$, and wherein $R^{10}$ being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring: and

$R^{14}$ is: hydrogen, $C_1$-$C_6$ alkyl or aryl.

24. A compound selected from the group consisting of No. 1-120 and 121:

| No. | Structure | Name |
|---|---|---|
| 1 |  | 3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid |
| 2 |  | 3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}- |

| No. | Structure | Name |
|---|---|---|
| | | 2-methyl-phenyl)-propionic acid |
| 3 |  | (4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid |
| 4 |  | (4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 5 |  | 3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid |
| 6 |  | (4-{2-[(5-Chloro-3-ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 7 |  | 4-{2-[(6-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 8 |  | 4-{2-[(7-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 9 |  | (4-{2-[(4-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 10 |  | (4-{2-[(5-Chloro-3-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 11 |  | (4-{2-[(5-Chloro-3-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid |
| 12 |  | 2-[4-(3-{[5-(4'-Fluoro-biphenyl-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-propyl)-phenoxy]-2-methyl-propionic acid |
| 13 |  | 2-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethyl}-phenoxy)-2-methyl-propionic acid |
| 14 |  | 2-(4-{3-[(3,5-Dimethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid |
| 15 |  | 2-(4-{3-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl- |

| No. | Structure | Name |
|---|---|---|
| | | propionic acid |
| 16 |  | 2-(4-{3-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(2,2,2-trifluoro-ethyl)-amino]-propyl}-phenoxy)-2-methyl-propionic acid |
| 17 |  | 2-(4-{2-[(3-Ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-3-propyl-phenoxy)-2-methyl-propionic acid |
| 18 |  | 2-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-2-methyl-propionic acid |
| 19 |  | 3-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid |
| 20 |  | [4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid |
| 21 |  | [4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic |

| No. | Structure | Name |
|---|---|---|
| | | acid |
| 22 |  | [4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid |
| 23 |  | (2-Methyl-4-{2-[(6-phenoxy-pyridine-3-sulfonyl)-propyl-amino]-ethylsulfanyl} phenoxy)-acetic acid |
| 24 |  | (2-Methyl-4-{2-[(5-methyl-1-phenyl-1H-pyrazole-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 25 |  | (2-Methyl-4-{2-[(4-oxazol-5-yl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 26 |  | (2-Methyl-4-{2-[propyl-(4-pyrazol-1-yl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 27 |  | (2-Methyl-4-{2-[(2-naphthalen-1-yl-ethanesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 28 |  | (2-Methyl-4-{2-[propyl-(4-trifluoromethylphenylmethanesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 29 |  | (4-{2-[(Biphenyl-3-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 30 |  | (4-{2-[(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 31 |  | [2-Methyl-4-(2-{[5-(2-methylsulfanyl-pyrimidin-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid |
| 32 |  | [2-Methyl-4-(2-{[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid |
| 33 |  | [2-Methyl-4-(2-{[5-(1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid |
| 34 |   | (R)-(2-Methyl-4-{1-methyl-2-[(3-methyl-5-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}- |

| No. | Structure | Name |
|---|---|---|
| | | phenoxy)-acetic acid |
| 35 |  chiral | (R)-3-(4-{2-[(6-Chloro-5-fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid |
| 36 |  chiral | (R)-(4-{2-[(6-Chloro-5-fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 37 |  | (4-{2-[(4-Bromo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 38 |  | (4-{2-[(3,4-Dichloro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 39 |  | (4-{2-[(4-Isopropyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 40 |  | (2-Methyl-4-{2-[(4-pentyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 41 |  | (4-{2-[(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 42 |  | (2-Methyl-4-{2-[propyl-(3-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 43 |  | (4-{2-[(4-Bromo-2-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 44 |  | (4-{2-[(3,4-Dibromo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 45 |  | (2-Methyl-4-{2-[propyl-(4-propyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 46 |  | (4-{2-[(2,4-Dichloro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 47 |  | (4-{2-[(4-Iodo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 48 |  | (4-{2-[(3-Chloro-4-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 49 |  | (4-{2-[(4-Bromo-2,5-difluoro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 50 |  chiral | (2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 51 |  chiral | (4-{2-[(3,4-Dichloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 52 |  | (2-Methyl-4-{2-[propyl-(2'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 53 |  | (2-Methyl-4-{2-[propyl-(3'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 54 |  | (2-Methyl-4-{2-[propyl-(4'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 55 |  | (4-{2-[(2'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 56 |  | (4-{2-[(4'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 57 |  | (2-Methyl-4-{2-[propyl-(4'-trifluoromethoxy-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 58 |  | (4-{2-[(3',4'-Dichloro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 59 |  | (4-{2-[(3'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 60 |  | (4-{2-[(2'-Chloro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 61 |  | (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 62 |  | (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic |

| No. | Structure | Name |
|---|---|---|
| | | acid |
| 63 |  | (4-{2-[(3'-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 64 |  | (4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 65 |  chiral | (2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 66 |  chiral | (2-Methyl-4-{1-methyl-2-[propyl-(4-propyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 67 |  chiral | (4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 68 |  chiral | (4-{2-[(3-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 69 |  | (4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 70 |  | (4-{2-[(4-Isobutyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 71 |  | (4-{2-[(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 72 |  | (4-{2-[(4-Bromo-3-chloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 73 |  | (4-{2-[(4-Butyl-3-chloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 74 |  | (4-{2-[(3-Chloro-4-isobutyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 75 |  | (4-{2-[(4-Bromo-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 76 |  | (4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 77 |   | (4-{2-[(2-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 78 |   | (4-{2-[(3-Chloro-4-propyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 79 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-propyl-phenoxy)-acetic acid |
| 80 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 81 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-trifluoromethyl-phenoxy)-acetic acid |
| 82 |  | [2-Methyl-4-(1-{[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-methyl}-propylsulfanyl)-phenoxy]-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 83 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 84 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 85 |  | (2-Methyl-4-{2-[(3-methyl-5-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 86 |  | (2-Methyl-4-{2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 87 |  | (4-{2-[(4-Ethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 88 |  | (2-Methyl-4-{2-[(2-methyl-4-trifluoromethoxy-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 89 |  | (2-Methyl-4-{2-[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 90 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 91 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(3-methyl-butyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 92 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclopropyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 93 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclobutyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 94 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclopropylmethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 95 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-pentyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 96 |  | (4-{2-[Butyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 97 |  | (4-{2-[(Biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 98 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-2-methyl-phenylsulfanyl)-acetic acid |
| 99 |  | (4-{3-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-2-methyl-phenoxy)-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 100 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid |
| 101 |  | 3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenyl)-propionic acid |
| 102 |  | 2-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid |
| 103 |  | 3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methoxy-phenyl)-propionic acid |
| 104 |  | (4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 105 |  | 3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenyl)-propionic acid |

| No. | Structure | Name |
|---|---|---|
| 106 |  | (4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid |
| 107 |  | (2-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 108 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-ethyl-phenoxy)-acetic acid |
| 109 |  | (2-Methyl-4-{2-[(naphthalene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid |
| 110 |  | (4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 111 |  | [3-Chloro-4-(1-{[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-methyl}-propylsulfanyl)-phenyl]- |

| No. | Structure | Name |
|---|---|---|
| | | acetic acid |
| 112 |  Chiral | (R)-(3-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-phenyl)-acetic acid |
| 113 |  | (3-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenyl)-acetic acid |
| 114 |  | [4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid |
| 115 |  | 3-[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid |
| 116 |  | 3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-butoxy}-2-methyl-phenyl)-propionic acid |
| 117 |  | [4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid |

| No. | Structure | Name |
|---|---|---|
| 118 |  | [4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methoxy-phenoxy]-acetic acid |
| 119 |  | (4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-phenethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 120 |  | (4-{2-[Benzyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid |
| 121 |  | [4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid |

25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Claims 1-24 or pharmaceutically acceptable salts, solvates or hydrates thereof.

26. A pharmaceutical composition comprising (1) a compound of Claim 1-24, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof; (2) a second therapeutic agent selected from the group consisting of insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents,

HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin; and (3) a pharmaceutically acceptable carrier.

27. A method of modulating a peroxisome proliferator activated receptor (PPAR), comprising the step of contacting the receptor with at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

28. The method of Claim 27, wherein the PPAR is a gamma receptor.

29. The method of Claim 27, wherein the PPAR is a delta-receptor.

30. The method of Claim 27, wherein the PPAR is a gamma and delta-receptor.

31. A method for treating or preventing a PPAR-gamma mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

32. A method for treating or preventing a PPAR-delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

33. A method for treating or preventing a PPAR-gamma and delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

34. A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

35. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1-24.

36. A method of treating or preventing diabetes mellitus in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1-24.

37. A method of treating or preventing cardiovascular disease in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

38. A method of treating or preventing syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

39. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1-24 and an effective amount of second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors,

statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin.

40. Use of a compound of Claims 1-24 and pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, for the manufacture of a medicament for the treatment of a condition modulated by a PPAR.